Cargando…

Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals

OBJECTIVE: Therapeutic HIV-1 immunization followed by latency reversal has been suggested as a strategy to eradicate HIV-1. Here we investigate the phylogenetic composition of the HIV-1 regions targeted by the therapeutic HIV-1 peptide vaccine Vacc-4x in participants in a clinical trial. DESIGN: Sev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Winckelmann, Anni, Morcilla, Vincent, Shao, Wei, Schleimann, Mariane H., Hojen, Jesper F., Schlub, Timothy E., Benton, Paul W., Østergaard, Lars, Søgaard, Ole S., Tolstrup, Martin, Palmer, Sarah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2018
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072375/ https://www.ncbi.nlm.nih.gov/pubmed/29762162 http://dx.doi.org/10.1097/QAD.0000000000001861

Ejemplares similares

Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations
por: Winckelmann, Anni, et al.
Publicado: (2017)

Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials
por: Rasmussen, Thomas A., et al.
Publicado: (2013)

A5 Peripheral blood cells contribute to HIV-1 viremia induced by romidepsin
por: Winckelmann, A., et al.
Publicado: (2017)

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
por: Søgaard, Ole S., et al.
Publicado: (2015)

Administration of a Toll-Like Receptor 9 Agonist Decreases the Proviral Reservoir in Virologically Suppressed HIV-Infected Patients
por: Winckelmann, Anni A., et al.
Publicado: (2013)

Immune checkpoints and the HIV-1 reservoir: proceed with caution
por: Olesen, Rikke, et al.
Publicado: (2016)

The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies
por: Martinsen, Janne Tegder, et al.
Publicado: (2020)

Impacts of HIV Cure Interventions on Viral Reservoirs in Tissues
por: Denton, Paul W., et al.
Publicado: (2019)

Broad activation of latent HIV-1 in vivo
por: Barton, Kirston, et al.
Publicado: (2016)

SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity
por: Nielsen, Stine SF, et al.
Publicado: (2021)

TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults
por: Offersen, Rasmus, et al.
Publicado: (2012)

Endotoxemia Is Associated with Altered Innate and Adaptive Immune Responses in Untreated HIV-1 Infected Individuals
por: Bukh, Anne Roslev, et al.
Publicado: (2011)

Single cell analysis reveals a subset of cytotoxic-like plasmacytoid dendritic cells in people with HIV-1
por: Cham, Lamin B., et al.
Publicado: (2023)

Redirector of Vaccine-induced Effector Responses (RoVER) for specific killing of cellular targets
por: Konrad, Christina V., et al.
Publicado: (2023)

Development of HIV-Resistant CAR T Cells by CRISPR/Cas-Mediated CAR Integration into the CCR5 Locus
por: Rothemejer, Frederik Holm, et al.
Publicado: (2023)

Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation
por: Gunst, Jesper D, et al.
Publicado: (2019)

HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02)
por: Mothe, Beatriz, et al.
Publicado: (2020)

SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses
por: Vibholm, Line K, et al.
Publicado: (2021)

Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Ex Vivo Lipopolysaccharide-Induced Inflammatory Responses
por: Brinkmann, Christel Rothe, et al.
Publicado: (2018)

DC-based immunotherapy as strategy to purge the HIV reservoir?
por: Søgaard, Ole S.
Publicado: (2019)

Comparison of HDAC inhibitors in clinical development: Effect on HIV production in latently infected cells and T-cell activation
por: Rasmussen, Thomas Aagaard, et al.
Publicado: (2013)

Acute Appendicitis as the Initial Clinical Presentation of Primary HIV-1 Infection
por: Schleimann, Mariane H, et al.
Publicado: (2018)

Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection
por: Zurek Munk-Madsen, Maria, et al.
Publicado: (2017)

The Impact of B-Cell Perturbations on Pneumococcal Conjugate Vaccine Response in HIV-Infected Adults
por: Johannesson, Thomas G., et al.
Publicado: (2012)

Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial
por: Gunst, Jesper D., et al.
Publicado: (2023)

Update on HIV reservoirs
por: Palmer, Sarah
Publicado: (2010)

High level of HIV-1 drug resistance among patients with HIV-1 and HIV-1/2 dual infections in Guinea-Bissau
por: Jespersen, Sanne, et al.
Publicado: (2015)

Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8(+) T cell immunity
por: Rosás-Umbert, Miriam, et al.
Publicado: (2022)

Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research
por: Denton, Paul W., et al.
Publicado: (2016)

Extensive characterization of HIV-1 reservoirs reveals links to plasma viremia before and during analytical treatment interruption
por: Cole, Basiel, et al.
Publicado: (2022)

Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients
por: Bjerg Christensen, Ane, et al.
Publicado: (2015)

In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial
por: Rosás-Umbert, Miriam, et al.
Publicado: (2020)

Nanobody‐mediated complement activation to kill HIV‐infected cells
por: Pedersen, Maria Lange, et al.
Publicado: (2023)

Immunomodulation with IL-7 and IL-15 in HIV-1 infection
por: Gunst, Jesper D., et al.
Publicado: (2023)

VaccImm: simulating peptide vaccination in cancer therapy
por: von Eichborn, Joachim, et al.
Publicado: (2013)

HIV-1 Genomes Are Enriched in Memory CD4(+) T-Cells with Short Half-Lives
por: Morcilla, Vincent, et al.
Publicado: (2021)

Romidepsin-induced neutrophilic urticaria
por: Scott, Brian, et al.
Publicado: (2016)

Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir
por: Neidleman, Jason, et al.
Publicado: (2020)

Strategies for enhancing CAR T cell expansion and persistence in HIV infection
por: Rothemejer, Frederik Holm, et al.
Publicado: (2023)

Are T cells the only HIV-1 reservoir?
por: Kandathil, Abraham Joseph, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_thnpcarlr0c9tggbkmk78arpbm